The market size of the global fabry disease treatment market in the year 2021 is valued at 1.44 billion and is predicted to reach 2.76 billion by the year 2030 at an 7.72% CAGR during the forecast period.
Fabry disease has been linked to several systemic signs and consequences, including metabolic abnormalities. In Fabry disease, sphingolipid metabolism is reduced, resulting in multiple organ failures and death. Government agencies have also launched programs in response to the disease's increasing consequences and the necessity for precise diagnosis and treatment. The creation of a potential biomarker for tracking and predicting disease severity and potential progression, as well as any treatment intervention's success, all help drive the fabry disease market forward. The increased financial burden of people with uncommon genetic disorders such as Fabry and the expensive treatment costs may limit the growth of the Fabry disease treatment market. Adopting advanced technology in research procedures is one of the primary factors of the fabry disease market growth. Complications in physiological systems, such as the cardiac and urinary systems, are projected to increase the demand for reliable therapy due to the hereditary nature and severity of the disease. Extensive R&D activities are one of the market's most valuable drivers. Incorporating innovative oral medication options can help overcome the relative lack of efficacy of enzyme replacement therapy, which is partly caused by antibody development. Furthermore, due to fabry disease patients' poor quality of life, there is significant patient readiness to pay for expensive therapies in the fabry disease market.
The fabry disease treatment market is segmented on the treatment. Based on treatment, the market is segmented into Enzyme Replacement Therapy (ERT) ((By Drug Type (Agalsidase Alpha, Agalsidase Beta), (By End-use (Physician office, Home settings)), and Chaperone Therapy.
The Enzyme replacement treatment segment witnessed growth at a rapid rate.
Enzyme replacement treatment grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time. ERT is intended to aid in identifying underlying disease causes and the breakdown of fatty molecules. Replagal enzyme replacement treatment, for example, was developed to replace human alpha-galactosidase A, a prevalent defect in fabry disease patients. Substantial application scope and the development of novel therapies will thus drive segmental growth over the forecasted term. The segment's dominance is supported by strong sales of fabrazyme and replagal, as well as the prospective approval of promising pipeline products. However, introducing new effective therapeutic options, such as gene therapies, is critical for a significant rise in patient benefits.
The North American Fabry disease treatment market holds a significant regional revenue share.
The North American Fabry disease treatment market is expected to register the highest market share in revenue soon. Higher acceptance of innovative therapeutics, improved healthcare facilities, and advantageous reimbursement policies contribute to the region's market growth. Coverage of pricey treatments such as fabrazyme by health insurance programs and beneficial governmental healthcare regulations also encourage pharmaceutical companies to enhance R&D spending on rare diseases. In addition, Asia Pacific is projected to grow rapidly in the global fabry disease treatment market. Government agencies have also launched programs in response to the disease's increasing consequences and the necessity for precise diagnosis and treatment. Because of rising healthcare spending and improved infrastructure, Asia Pacific presents enormous growth prospects for pharmaceutical companies.
Some major key players in the Fabry disease treatment market are Sanofi SA, Takeda Pharmaceuticals Co, Amicus Therapeutics, Inc, JCR Pharmaceuticals Co Ltd, ISU Abxis Co. Ltd., Avrobio Inc., Greenovation Biotech GmbH, Idorsia Pharmaceuticals Ltd., Moderna Therapeutics Inc., Protalix Biotherapeutics Inc., and Shire Plc.